Abbott Laboratories (ABT) EV/FCF Ratio: 24.92x
Is Abbott Laboratories’s EV/FCF ratio high or low?
Abbott Laboratories's EV/FCF ratio of 24.92x is 20% below its 5-year average of 31.02x, near the low end of its 5-year range (20.72x–46.60x).
As of Friday, June 12, 2026. 19.51% below its 12-month average of 30.96x.
ABT EV/FCF Ratio Chart
ABT Average EV/FCF Ratio Chart
ABT Current vs Average EV/FCF Ratio Chart
ABT EV/FCF Ratio Metrics
EV/FCF RATIO
24.92x
EV/FCF RATIO AVG TTM
30.96x
EV/FCF RATIO AVG 3Y
34.90x
EV/FCF RATIO AVG 5Y
31.02x
EV/FCF RATIO AVG 10Y
33.44x
EV/FCF RATIO AVG 15Y
28.99x
EV/FCF RATIO AVG 20Y
24.24x
CURRENT VS TTM AVG
-19.51%
CURRENT VS 3Y AVG
-28.59%
CURRENT VS 5Y AVG
-19.67%
CURRENT VS 10Y AVG
-25.48%
CURRENT VS 15Y AVG
-14.05%
CURRENT VS 20Y AVG
+2.81%
ABT Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | $156.15B | 24.92x | 30.96x | 34.90x | 31.02x |
| Gilead Sciences, Inc. (GILD) | $156.28B | 16.85x | 18.52x | 16.04x | 14.51x |
| Pfizer Inc. (PFE) | $149.18B | 22.43x | 19.77x | 27.32x | 21.37x |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 51.70x | 79.55x | 160.31x | 125.13x |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 32.21x | 35.74x | 34.61x | 34.76x |
| CVS Health Corporation (CVS) | $129.25B | 26.69x | 27.82x | 26.94x | 21.13x |
| Danaher Corporation (DHR) | $128.27B | 26.72x | 31.95x | 32.29x | 30.49x |
| Amgen Inc. (AMGN) | $191.09B | 27.67x | 22.37x | 24.94x | 22.50x |
| Bristol-Myers Squibb Company (BMY) | $116.19B | 12.69x | 10.44x | 11.39x | 12.31x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $112.95B | 29.80x | 32.26x | 28.31x | 25.04x |
Cash Flow Valuation Comparison
EV/FCF
24.9x
P/FCF
21.2x
FCF Yield
4.71%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Abbott Laboratories EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Abbott Laboratories (ABT)?
- The EV/FCF ratio for ABT stock is 24.92x.
- Is Abbott Laboratories's EV/FCF ratio high or low?
- Abbott Laboratories's EV/FCF ratio of 24.92x is 20% below its 5-year average of 31.02x, near the low end of its 5-year range (20.72x–46.60x).
- What is the TTM average EV/FCF ratio for Abbott Laboratories (ABT)?
- The TTM average EV/FCF ratio for ABT stock is 30.96x.
- What is the 3Y average EV/FCF ratio for Abbott Laboratories (ABT)?
- The 3Y average EV/FCF ratio for ABT stock is 34.90x.
- What is the 5Y average EV/FCF ratio for Abbott Laboratories (ABT)?
- The 5Y average EV/FCF ratio for ABT stock is 31.02x.
- What is the 10Y average EV/FCF ratio for Abbott Laboratories (ABT)?
- The 10Y average EV/FCF ratio for ABT stock is 33.44x.
- What is the 15Y average EV/FCF ratio for Abbott Laboratories (ABT)?
- The 15Y average EV/FCF ratio for ABT stock is 28.99x.
- What is the 20Y average EV/FCF ratio for Abbott Laboratories (ABT)?
- The 20Y average EV/FCF ratio for ABT stock is 24.24x.
Abbott Laboratories EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-11 | 24.92x |
| 2026-06-10 | 24.81x |
| 2026-06-09 | 25.30x |
| 2026-06-08 | 25.12x |
| 2026-06-05 | 25.26x |
| 2026-06-04 | 25.19x |
| 2026-06-03 | 24.29x |
| 2026-06-02 | 24.29x |
| 2026-06-01 | 24.48x |
| 2026-05-29 | 23.96x |
| 2026-05-28 | 24.13x |
| 2026-05-27 | 23.98x |
| 2026-05-26 | 24.21x |
| 2026-05-22 | 24.39x |
| 2026-05-21 | 24.48x |
| 2026-05-20 | 24.62x |
| 2026-05-19 | 24.72x |
| 2026-05-18 | 24.51x |
| 2026-05-15 | 23.69x |
| 2026-05-14 | 23.80x |
| 2026-05-13 | 23.54x |
| 2026-05-12 | 23.67x |
| 2026-05-11 | 23.24x |
| 2026-05-08 | 23.66x |
| 2026-05-07 | 24.30x |
| 2026-05-06 | 24.13x |
| 2026-05-05 | 24.33x |
| 2026-05-04 | 24.42x |
| 2026-05-01 | 24.88x |
| 2026-04-30 | 25.19x |
| 2026-04-29 | 25.32x |
| 2026-04-28 | 23.06x |
| 2026-04-27 | 22.81x |
| 2026-04-24 | 22.41x |
| 2026-04-23 | 22.73x |
| 2026-04-22 | 22.55x |
| 2026-04-21 | 22.79x |
| 2026-04-20 | 23.56x |
| 2026-04-17 | 23.76x |
| 2026-04-16 | 23.44x |
| 2026-04-15 | 24.88x |
| 2026-04-14 | 24.76x |
| 2026-04-13 | 24.67x |
| 2026-04-10 | 24.58x |
| 2026-04-09 | 25.15x |
| 2026-04-08 | 25.35x |
| 2026-04-07 | 24.94x |
| 2026-04-06 | 25.05x |
| 2026-04-02 | 25.19x |
| 2026-04-01 | 25.07x |
| 2026-03-31 | 25.14x |
| 2026-03-30 | 24.95x |
| 2026-03-27 | 25.45x |
| 2026-03-26 | 25.59x |
| 2026-03-25 | 25.65x |
| 2026-03-24 | 25.47x |
| 2026-03-23 | 25.65x |
| 2026-03-20 | 25.80x |
| 2026-03-19 | 26.21x |
| 2026-03-18 | 26.51x |
| 2026-03-17 | 27.04x |
| 2026-03-16 | 26.86x |
| 2026-03-13 | 26.41x |
| 2026-03-12 | 26.43x |
| 2026-03-11 | 26.93x |
| 2026-03-10 | 27.00x |
| 2026-03-09 | 27.50x |
| 2026-03-06 | 26.77x |
| 2026-03-05 | 27.12x |
| 2026-03-04 | 27.60x |
| 2026-03-03 | 27.72x |
| 2026-03-02 | 27.84x |
| 2026-02-27 | 28.37x |
| 2026-02-26 | 28.35x |
| 2026-02-25 | 28.00x |
| 2026-02-24 | 27.95x |
| 2026-02-23 | 28.12x |
| 2026-02-20 | 27.39x |
| 2026-02-19 | 29.15x |
| 2026-02-18 | 29.43x |
| 2026-02-17 | 29.17x |
| 2026-02-13 | 29.28x |
| 2026-02-12 | 28.97x |
| 2026-02-11 | 29.51x |
| 2026-02-10 | 29.18x |
| 2026-02-09 | 28.87x |
| 2026-02-06 | 28.81x |
| 2026-02-05 | 28.37x |
| 2026-02-04 | 28.14x |
| 2026-02-03 | 28.35x |
| 2026-02-02 | 28.45x |
| 2026-01-30 | 28.42x |
| 2026-01-29 | 27.61x |
| 2026-01-28 | 27.60x |
| 2026-01-27 | 28.16x |
| 2026-01-26 | 28.29x |
| 2026-01-23 | 27.95x |
| 2026-01-22 | 28.25x |
| 2026-01-21 | 31.31x |
| 2026-01-20 | 31.42x |
| 2026-01-16 | 31.57x |
| 2026-01-15 | 32.02x |
| 2026-01-14 | 32.39x |
| 2026-01-13 | 32.21x |
| 2026-01-12 | 32.30x |
| 2026-01-09 | 32.62x |
| 2026-01-08 | 32.69x |
| 2026-01-07 | 32.91x |
| 2026-01-06 | 33.10x |
| 2026-01-05 | 32.76x |
| 2026-01-02 | 32.19x |
| 2025-12-31 | 32.47x |
| 2025-12-30 | 32.59x |
| 2025-12-29 | 32.28x |
| 2025-12-26 | 32.35x |
| 2025-12-24 | 32.34x |
| 2025-12-23 | 32.28x |
| 2025-12-22 | 32.45x |
| 2025-12-19 | 32.51x |
| 2025-12-18 | 32.42x |
| 2025-12-17 | 32.82x |
| 2025-12-16 | 32.86x |
| 2025-12-15 | 33.27x |
| 2025-12-12 | 32.51x |
| 2025-12-11 | 31.96x |
| 2025-12-10 | 31.77x |
| 2025-12-09 | 31.44x |
| 2025-12-08 | 31.66x |
| 2025-12-05 | 32.41x |
| 2025-12-04 | 32.49x |
| 2025-12-03 | 32.47x |
| 2025-12-02 | 32.73x |
| 2025-12-01 | 33.15x |
| 2025-11-28 | 33.38x |
| 2025-11-26 | 33.29x |
| 2025-11-25 | 33.16x |
| 2025-11-24 | 32.95x |
| 2025-11-21 | 33.18x |
| 2025-11-20 | 32.13x |
| 2025-11-19 | 32.68x |
| 2025-11-18 | 33.66x |
| 2025-11-17 | 33.66x |
| 2025-11-14 | 33.81x |
| 2025-11-13 | 33.47x |
| 2025-11-12 | 33.36x |
| 2025-11-11 | 32.90x |
| 2025-11-10 | 32.62x |
| 2025-11-07 | 32.74x |
| 2025-11-06 | 32.38x |
| 2025-11-05 | 32.28x |
| 2025-11-04 | 32.59x |
| 2025-11-03 | 32.10x |
| 2025-10-31 | 32.04x |
| 2025-10-30 | 32.31x |
| 2025-10-29 | 32.25x |
| 2025-10-28 | 33.68x |
| 2025-10-27 | 33.83x |
| 2025-10-24 | 33.74x |
| 2025-10-23 | 33.61x |
| 2025-10-22 | 34.03x |
| 2025-10-21 | 33.92x |
| 2025-10-20 | 34.43x |
| 2025-10-17 | 34.18x |
| 2025-10-16 | 33.94x |
| 2025-10-15 | 34.41x |
| 2025-10-14 | 35.40x |
| 2025-10-13 | 34.91x |
| 2025-10-10 | 35.22x |
| 2025-10-09 | 35.41x |
| 2025-10-08 | 35.66x |
| 2025-10-07 | 35.34x |
| 2025-10-06 | 35.52x |
| 2025-10-03 | 35.74x |
| 2025-10-02 | 35.33x |
| 2025-10-01 | 35.45x |
| 2025-09-30 | 35.57x |
| 2025-09-29 | 35.36x |
| 2025-09-26 | 35.47x |
| 2025-09-25 | 35.41x |
| 2025-09-24 | 35.56x |
| 2025-09-23 | 36.08x |
| 2025-09-22 | 36.27x |
| 2025-09-19 | 36.12x |
| 2025-09-18 | 35.74x |
| 2025-09-17 | 35.63x |
| 2025-09-16 | 35.27x |
| 2025-09-15 | 34.90x |
| 2025-09-12 | 35.52x |
| 2025-09-11 | 35.24x |
| 2025-09-10 | 34.39x |
| 2025-09-09 | 35.06x |
| 2025-09-08 | 35.12x |
| 2025-09-05 | 35.32x |
| 2025-09-04 | 35.28x |
| 2025-09-03 | 35.12x |
| 2025-09-02 | 34.93x |
| 2025-08-29 | 35.24x |
| 2025-08-28 | 34.91x |
| 2025-08-27 | 34.93x |
| 2025-08-26 | 34.97x |
| 2025-08-25 | 35.04x |
| 2025-08-22 | 35.23x |
| 2025-08-21 | 35.07x |
| 2025-08-20 | 35.19x |
| 2025-08-19 | 34.88x |
| 2025-08-18 | 34.63x |
| 2025-08-15 | 35.01x |
| 2025-08-14 | 34.37x |
| 2025-08-13 | 34.40x |
| 2025-08-12 | 34.82x |
| 2025-08-11 | 34.91x |
| 2025-08-08 | 35.66x |
| 2025-08-07 | 35.09x |
| 2025-08-06 | 34.80x |
| 2025-08-05 | 34.73x |
| 2025-08-04 | 34.54x |
| 2025-08-01 | 33.86x |
| 2025-07-31 | 33.57x |
| 2025-07-30 | 34.18x |
| 2025-07-29 | 34.61x |
| 2025-07-28 | 34.17x |
| 2025-07-25 | 34.22x |
| 2025-07-24 | 33.98x |
| 2025-07-23 | 34.03x |
| 2025-07-22 | 34.01x |
| 2025-07-21 | 33.66x |
| 2025-07-18 | 33.47x |
| 2025-07-17 | 32.64x |
| 2025-07-16 | 35.58x |
| 2025-07-15 | 35.52x |
| 2025-07-14 | 35.66x |
| 2025-07-11 | 35.66x |
| 2025-07-10 | 36.07x |
| 2025-07-09 | 35.97x |
| 2025-07-08 | 36.01x |
| 2025-07-07 | 36.10x |
| 2025-07-03 | 36.29x |
| 2025-07-02 | 36.21x |
| 2025-07-01 | 36.77x |
| 2025-06-30 | 36.71x |
| 2025-06-27 | 36.28x |
| 2025-06-26 | 36.09x |
| 2025-06-25 | 37.07x |
| 2025-06-24 | 37.25x |
| 2025-06-23 | 35.98x |
| 2025-06-20 | 35.91x |
| 2025-06-18 | 35.76x |
| 2025-06-17 | 35.73x |
| 2025-06-16 | 36.18x |
| 2025-06-13 | 36.60x |
| 2025-06-12 | 36.82x |
| 2025-06-11 | 36.51x |
| 2025-06-10 | 36.21x |
| 2025-06-09 | 36.02x |
| 2025-06-06 | 36.07x |
| 2025-06-05 | 36.16x |
| 2025-06-04 | 35.91x |
| 2025-06-03 | 36.10x |
| 2025-06-02 | 36.07x |
| 2025-05-30 | 36.07x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford